INDEMNIFICATION AGREEMENT Effective Date: [_______]Indemnification Agreement • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMMICATION AGREEMENT (this “Agreement”), is made as of the Effective Date set forth above, between OCUPHIRE PHARMA INC., a Delaware corporation (the “Company”), whose address is 6894 Lakemont Circle, West Bloomfield, MI 48323, and [_______] (“Indemnitee”).
Amended and Restated Employment AgreementEmployment Agreement • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Michigan
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) by and between Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and Bernhard Hoffmann (the “Executive”) is signed by the Company and the Executive and is entered into on June 17, 2020 and made effective as of the Merger Closing Date (as defined below) (the “Effective Date”).
DUKE & DUKE OFFICE BUILDING LEASELease Agreement • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LEASE is made between the Landlord and Tenant hereinafter identified in Paragraph 1(b) and 1(c) hereof, respectively, and constitutes a Lease between the parties of the “demised premises” in the “Building” as defined in Paragraph 2 hereof on the terms and conditions and with and subject to the covenants and agreements of the parties hereinafter set forth.
FIRST AMENDMENT TO SUBLICENSE AGREEMENTSublicense Agreement • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations
This First Amendment to Sublicense Agreement (this “Amendment”) is made effective as of June 4, 2020, by and between Apexian Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 20 North Meridian Street, Suite 801, Indianapolis, IN 46204 (“Sublicensor”), and Ocuphire Pharma, Inc., a Delaware corporation, having its principal place of business at 37000 Grand River Avenue, Suite 120, Farmington Hills, MI 48335 (“Sublicensee”).
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks. The identified confidential portions (i) are not material and (ii) would be competitively...Sublicense Agreement • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Michigan
THIS SUBLICENSE AGREEMENT (this “Agreement”) is made as of January 21, 2020 (the “Effective Date”), by and between Apexian Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 20 North Meridian Street, Suite 801, Indianapolis, IN 46204 (“Sublicensor”), and Ocuphire Pharma, Inc., a Delaware corporation, having its principal place of business at 37000 Grand River Avenue, Suite 120, Farmington Hills, MI 48335 (“Sublicensee”). Sublicensor and Sublicensee are each individually referred to herein without distinction as a “Party” and collectively as the “Parties.”
Stockholders AgreementStockholders Agreement • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS STOCKHOLDERS AGREEMENT (the “Agreement”) is entered into effective as of April 10, 2018 (the “Effective Date”) by and among Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and the holders of the Company’s common stock as listed on Schedule A attached hereto (each, a “Stockholder” and collectively, the “Stockholders”).
AMENDED AND RESTATED MEZZ NOTE PURCHASE AGREEMENTMezz Note Purchase Agreement • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Michigan
THIS AMENDED AND RESTATED MEZZ NOTE PURCHASE AGREEMENT (this “Agreement”) is made as of January 22, 2019 (the “Effective Date”) by and among OCUPHIRE PHARMA, INC., a Delaware corporation, whose address is 6894 Lakemont Circle West Bloomfield, MI (the “Company”), and each of the persons and entities listed on EXHIBIT A attached hereto, as it may be amended as hereinafter provided (each a “Purchaser” and, collectively, the “Purchasers”).
conversion AGREEMENTConversion Agreement • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Conversion Agreement (this “Agreement”) is made as of June 8, 2020, by and among Ocuphire Pharma, Inc., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, whose names are set forth on the Schedule of Purchasers (the “Schedule of Purchasers”) on Exhibit A attached hereto (collectively, the “Purchasers” and each, without distinction, a “Purchaser”).
FIRST AMENDMENT TO AMENDED AND RESTATED MEZZ NOTE PURCHASE AGREEMENT AND MEZZ CONVERTIBLE SUBORDINATED PROMISSORY NOTESMezz Note Purchase Agreement • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Michigan
This FIRST AMENDMENT TO AMENDED AND RESTATED MEZZ NOTE PURCHASE AGREEMENT (this “First Amendment”) is made as of November 20, 2019, by and among OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, whose names are set forth on the Schedule of Purchasers (the “Schedule of Purchasers”) attached as Exhibit A to the Amended and Restated Mezz Note Purchase Agreement (collectively, the “Purchasers” and each, without distinction, a “Purchaser”).
FIRST LEASE AMENDMENTLease Amendment • July 6th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations
This Lease Amendment made this 29th day of October, 2019 by and between DUKE & DUKE, a Limited Partnership, of 37000 Grand River Avenue, Suite 360, Farmington Hills, MI 45335, as “LANDLORD” and Ocuphire Pharma, Inc. of 37000 Grand River Avenue, Suite 120, Farmington Hills, MI 48335, as “TENANT”.
